BRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled

Reuters

14 Dec 2024

BRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of <a href="https://laohu8.com/S/CTLT">Catalent</a> Have Been Fulfilled

Dec 14 (Reuters) - Novo Nordisk NOVOb.CO:

NOVO NORDISK: ALL REGULATORY CLOSING CONDITIONS RELATING TO REVIEW OF NOVO HOLDINGS A/S'S PENDING ACQUISITION OF CATALENT HAVE BEEN FULFILLED
NOVO NORDISK: PARTIES ARE NOW FREE TO CLOSE TRANSACTION AS WELL AS NOVO NORDISK'S SUBSEQUENT ACQUISITION OF 3 CATALENT MANUFACTURING SITES FROM NOVO HOLDINGS
NOVO NORDISK: FOR 2025, ACQUISITION IS EXPECTED TO HAVE A MID SINGLE-DIGIT NEGATIVE IMPACT ON OPERATING PROFIT GROWTH
NOVO NORDISK: ACQUISITION WILL BE MAINLY DEBT-FINANCED, WITH INTEREST PAYMENTS NEGATIVELY IMPACTING NET FINANCIAL ITEMS
NOVO NORDISK: NOT EXPECTING TO INITIATE A SHARE BUYBACK PROGRAMME IN 2025

Source text: ID:nGNE8XVhg0

Further company coverage: CTLT.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2491300165"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2491300165\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2491300165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-14 13:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491300165","market":"us","top_or_hot":-1,"title":"BRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> Have Been Fulfilled</title></head><body><p><span>Dec 14 (Reuters)</span><span> - </span>Novo Nordisk <span>NOVOb<a href=\"https://laohu8.com/S/02403\">.C</a>O</span>: </p><ul><li><p>NOVO NORDISK: ALL REGULATORY CLOSING CONDITIONS RELATING TO REVIEW OF NOVO HOLDINGS A/S'S PENDING ACQUISITION OF CATALENT HAVE BEEN FULFILLED</p></li><li><p>NOVO NORDISK: PARTIES ARE NOW FREE TO CLOSE TRANSACTION AS WELL AS NOVO NORDISK'S SUBSEQUENT ACQUISITION OF 3 CATALENT MANUFACTURING SITES FROM NOVO HOLDINGS</p></li><li><p>NOVO NORDISK: FOR 2025, ACQUISITION IS EXPECTED TO HAVE A MID SINGLE-DIGIT NEGATIVE IMPACT ON OPERATING PROFIT GROWTH</p></li><li><p>NOVO NORDISK: ACQUISITION WILL BE MAINLY DEBT-FINANCED, WITH INTEREST PAYMENTS NEGATIVELY IMPACTING NET FINANCIAL ITEMS</p></li><li><p>NOVO NORDISK: NOT EXPECTING TO INITIATE A SHARE BUYBACK PROGRAMME IN 2025</p></li></ul><p>Source text: <span>ID:nGNE8XVhg0</span></p><p>Further company coverage: <span>CTLT.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-14 13:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> Have Been Fulfilled</title></head><body><p><span>Dec 14 (Reuters)</span><span> - </span>Novo Nordisk <span>NOVOb<a href=\"https://laohu8.com/S/02403\">.C</a>O</span>: </p><ul><li><p>NOVO NORDISK: ALL REGULATORY CLOSING CONDITIONS RELATING TO REVIEW OF NOVO HOLDINGS A/S'S PENDING ACQUISITION OF CATALENT HAVE BEEN FULFILLED</p></li><li><p>NOVO NORDISK: PARTIES ARE NOW FREE TO CLOSE TRANSACTION AS WELL AS NOVO NORDISK'S SUBSEQUENT ACQUISITION OF 3 CATALENT MANUFACTURING SITES FROM NOVO HOLDINGS</p></li><li><p>NOVO NORDISK: FOR 2025, ACQUISITION IS EXPECTED TO HAVE A MID SINGLE-DIGIT NEGATIVE IMPACT ON OPERATING PROFIT GROWTH</p></li><li><p>NOVO NORDISK: ACQUISITION WILL BE MAINLY DEBT-FINANCED, WITH INTEREST PAYMENTS NEGATIVELY IMPACTING NET FINANCIAL ITEMS</p></li><li><p>NOVO NORDISK: NOT EXPECTING TO INITIATE A SHARE BUYBACK PROGRAMME IN 2025</p></li></ul><p>Source text: <span>ID:nGNE8XVhg0</span></p><p>Further company coverage: <span>CTLT.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTLT","symbol_name":"Catalent","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241214:nFWN3NE11O:1","article_id":"2491300165","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491300165","pubTimestamp":1734153126,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been FulfilledDec 14 (Reuters) - Novo Nordisk NOVOb.CO: NOVO NO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTLT":"Catalent","BK4585":"ETF&股票定投概念","BK4530":"医药外包概念","BK4588":"碎股","BK4007":"制药"},"translate_title":"简报-诺和诺德表示，与Novo Holdings A/S即将收购Catalent相关的所有监管成交条件均已满足","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTLT":0.9},"content_text":"BRIEF-Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been FulfilledDec 14 (Reuters) - Novo Nordisk NOVOb.CO: NOVO NORDISK: ALL REGULATORY CLOSING CONDITIONS RELATING TO REVIEW OF NOVO HOLDINGS A/S'S PENDING ACQUISITION OF CATALENT HAVE BEEN FULFILLEDNOVO NORDISK: PARTIES ARE NOW FREE TO CLOSE TRANSACTION AS WELL AS NOVO NORDISK'S SUBSEQUENT ACQUISITION OF 3 CATALENT MANUFACTURING SITES FROM NOVO HOLDINGSNOVO NORDISK: FOR 2025, ACQUISITION IS EXPECTED TO HAVE A MID SINGLE-DIGIT NEGATIVE IMPACT ON OPERATING PROFIT GROWTHNOVO NORDISK: ACQUISITION WILL BE MAINLY DEBT-FINANCED, WITH INTEREST PAYMENTS NEGATIVELY IMPACTING NET FINANCIAL ITEMSNOVO NORDISK: NOT EXPECTING TO INITIATE A SHARE BUYBACK PROGRAMME IN 2025Source text: ID:nGNE8XVhg0Further company coverage: CTLT.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}